186 related articles for article (PubMed ID: 36147313)
1. A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage I-III hepatocellular carcinoma.
Chen XX; Zhang BH; Lu YC; Li ZQ; Chen CY; Yang YC; Chen YJ; Ma D
Front Pharmacol; 2022; 13():939912. PubMed ID: 36147313
[No Abstract] [Full Text] [Related]
2. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma.
Xu Q; Xu H; Deng R; Li N; Mu R; Qi Z; Shen Y; Wang Z; Wen J; Zhao J; Weng D; Huang W
Cancer Cell Int; 2021 Apr; 21(1):190. PubMed ID: 33794886
[TBL] [Abstract][Full Text] [Related]
3. Profiles of prognostic alternative splicing signature in hepatocellular carcinoma.
Wu F; Chen Q; Liu C; Duan X; Hu J; Liu J; Cao H; Li W; Li H
Cancer Med; 2020 Mar; 9(6):2171-2180. PubMed ID: 31975560
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma.
Liu Z; Ye J; Khan AA; Chen J; Zhou L; Zheng S; Xu X
Med Sci Monit; 2021 Aug; 27():e930052. PubMed ID: 34407065
[TBL] [Abstract][Full Text] [Related]
5. Analysis of relapse-associated alternative mRNA splicing and construction of a prognostic signature predicting relapse in I-III colon cancer.
Zhang Z; Feng Q; Jia C; Zheng P; Lv Y; Mao Y; Xu Y; He G; Xu J
Genomics; 2020 Nov; 112(6):4032-4040. PubMed ID: 32645524
[TBL] [Abstract][Full Text] [Related]
6. Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma.
Wang X; Qian J; Yao N; Pocha C; Kang KJ; Angelico R; Zhu G
Ann Transl Med; 2022 May; 10(10):595. PubMed ID: 35722420
[TBL] [Abstract][Full Text] [Related]
7. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
8. A signature predicting relapse based on integrated analysis on relapse-associated alternative mRNA splicing in I-III rectal cancer.
Zhang Z; Ji M; Lv Y; Feng Q; Zheng P; Mao Y; Xu Y; He G; Xu J
Genomics; 2020 Sep; 112(5):3274-3283. PubMed ID: 32544549
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Novel Four-Gene Signature Correlated With the Prognosis of Patients With Hepatocellular Carcinoma: A Comprehensive Analysis.
Zhu W; Ru L; Ma Z
Front Oncol; 2021; 11():626654. PubMed ID: 33777771
[TBL] [Abstract][Full Text] [Related]
10. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
Yu S; Cai L; Liu C; Gu R; Cai L; Zhuo L
Mol Med; 2021 Apr; 27(1):36. PubMed ID: 33832428
[TBL] [Abstract][Full Text] [Related]
11. An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma.
Lin Z; Xu Q; Miao D; Yu F
Front Oncol; 2021; 11():644416. PubMed ID: 33828988
[TBL] [Abstract][Full Text] [Related]
12. Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis.
Wang W; Pan F; Lin X; Yuan J; Tao C; Wang R
Front Genet; 2022; 13():907331. PubMed ID: 35938001
[No Abstract] [Full Text] [Related]
13. Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data.
Zhu GQ; Zhou YJ; Qiu LX; Wang B; Yang Y; Liao WT; Luo YH; Shi YH; Zhou J; Fan J; Dai Z
Carcinogenesis; 2019 Sep; 40(9):1077-1085. PubMed ID: 31099827
[TBL] [Abstract][Full Text] [Related]
14. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
15. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.
Zhang C; Li D; Yu R; Li C; Song Y; Chen X; Fan Y; Liu Y; Qu X
Front Immunol; 2021; 12():651033. PubMed ID: 34054812
[TBL] [Abstract][Full Text] [Related]
16. An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients.
Guo C; Dong C; Zhang J; Wang R; Wang Z; Zhou J; Wang W; Ji B; Ma B; Ge Y; Wang Z
Front Med (Lausanne); 2021; 8():716869. PubMed ID: 34350203
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
18. Prognostic alternative splicing signature reveals the landscape of immune infiltration in Pancreatic Cancer.
Wang L; Bi J; Li X; Wei M; He M; Zhao L
J Cancer; 2020; 11(22):6530-6544. PubMed ID: 33046974
[No Abstract] [Full Text] [Related]
19. A Mutation-Related Long Noncoding RNA Signature of Genome Instability Predicts Immune Infiltration and Hepatocellular Carcinoma Prognosis.
Wu J; Ren X; Wang N; Zhou R; Chen M; Cai Y; Lin S; Zhang H; Xie X; Dang C; Zhang S; Zhou Z
Front Genet; 2021; 12():779554. PubMed ID: 34880908
[No Abstract] [Full Text] [Related]
20. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
[No Abstract] [Full Text] [Related]
[Next] [New Search]
